TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6132449

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin (DOX)
Number of subjects: 0
Study: 29644545

Group type: EXPERIMENTAL
Intervention: Adaptive parenting program (group sessions and one-to-one component including online videos and follow-up telephone calls)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: One-to-one component of the intervention
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Program modifications
Number of subjects: 15
Study: 27494528

Group type: EXPERIMENTAL
Intervention: Video-Based Cognitive Behavioral Therapy for Insomnia (VCBT-I)
Number of subjects: 80
Study: 27062682

Group type: EXPERIMENTAL
Intervention: Worry Outcome Journal (WOJ)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Thought Log (TL)
Number of subjects: 51
Study: 24629036

Group type: EXPERIMENTAL
Intervention: Higher DCI (above the median)
Number of subjects: 1456

Group type: COMPARATOR
Intervention: Lower DCI (below the median)
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Mean DCI
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: DCI
Number of subjects: 1456
Study: 22146893

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 45
Study: 19664301

Group type: EXPERIMENTAL
Intervention: 6 weeks refeeding
Number of subjects: 169

Group type: COMPARATOR
Intervention: 1 week refeeding
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 169
Study: 18050245

Group type: EXPERIMENTAL
Intervention: Escitalopram (10‐20 mg/day)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75‐225 mg/day)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 16351798

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 216

Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 216
Study: 11796272

Group type: EXPERIMENTAL
Intervention: 7F tail stent with an 18F Councill nephrostomy tube (group B, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 24F re‐entry Malecot nephrostomy tube (group A, n = 20)
Number of subjects: 40
Study: 10190769

Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg x d(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7671564

Group type: EXPERIMENTAL
Intervention: Mannitol infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin infusion (0.5 m-units/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin superimposed on mannitol infusion
Number of subjects: 6
Study: 29619793

Group type: EXPERIMENTAL
Intervention: FIFA 11+ (N=10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional dynamic WU exercise (Control, N=11)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: FIFA 11+ and Conventional dynamic WU exercises
Number of subjects: 21
Study: 30894898

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (3 sessions per week, 45 minutes each, for 8 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 80
Study: 27417920

Group type: EXPERIMENTAL
Intervention: Diverted patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (40 normal male volunteers)
Number of subjects: 100
Study: 24690084

Group type: EXPERIMENTAL
Intervention: Miller blade
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Macintosh blade
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both blades
Number of subjects: 120
Study: 21549557

Group type: EXPERIMENTAL
Intervention: Uncemented fully porous‐coated composite stem (Epoch; Zimmer)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Uncemented proximally porous‐coated solid stem (Anatomic; Zimmer)
Number of subjects: 38
Study: 19647525

Group type: EXPERIMENTAL
Intervention: Acute sleep deprivation
Number of subjects: 102

Group type: COMPARATOR
Intervention: No sleep deprivation (control)
Number of subjects: 102
Study: 18092435

Group type: EXPERIMENTAL
Intervention: Intraumbilical vein oxytocin (10 units diluted with 10 ml of normal saline)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous infusion of oxytocin (10 units in 500 ml of normal saline)
Number of subjects: 100
Study: 15207988

Group type: EXPERIMENTAL
Intervention: Physical activity from 1982 to 1995
Number of subjects: 171

Group type: COMPARATOR
Intervention: Obesity from 1982 to 1995
Number of subjects: 171
Study: 11443192

Group type: EXPERIMENTAL
Intervention: Pulsatile iv GnRH administration (0.1 microg/kg every 90 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9532329

Group type: EXPERIMENTAL
Intervention: Meropenem administered as intravenous infusions at a dose of 1 g every 8 hours for 4 to 41 days (median of 11 days)
Number of subjects: 11
Study: 8033141

Group type: EXPERIMENTAL
Intervention: M‐CSF at 100 micrograms/kg/day and gamma‐IFN at 0.1 mg/m2/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: M‐CSF at 140 micrograms/kg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: M‐CSF at 100 micrograms/kg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: M‐CSF therapy alone at the same dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined therapy with M‐CSF and gamma‐IFN
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: M‐CSF and gamma‐IFN therapy
Number of subjects: 36
Study: 2721018

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 38

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 38
Study: 1132079

Group type: EXPERIMENTAL
Intervention: High sodium intake (410 mEq/24hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low sodium intake (10 mEq/24hr)
Number of subjects: 6
Study: 29933355

Group type: EXPERIMENTAL
Intervention: Caffeine (800 mg)
Number of subjects: 15
Study: 31254137

Group type: EXPERIMENTAL
Intervention: Very early analgesia (VEA) group
Number of subjects: 306

Group type: COMPARATOR
Intervention: Postoperative analgesia (PA) group
Number of subjects: 306
Study: 27610609

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate 875 mg/125 mg twice daily (BID) for 14 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo capsules for 14 days
Number of subjects: 32
Study: 25887964

Group type: EXPERIMENTAL
Intervention: 12-month WIC enhanced plus internet-based weight loss intervention
Number of subjects: 408

Group type: COMPARATOR
Intervention: 12-month standard WIC intervention
Number of subjects: 408
Study: 23216297

Group type: EXPERIMENTAL
Intervention: Body empowerment intervention (5 weekly sessions)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (n=99)
Number of subjects: 198
Study: 21524316

Group type: EXPERIMENTAL
Intervention: PRECEDE model
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional model
Number of subjects: 600
Study: 17868402

Group type: EXPERIMENTAL
Intervention: Surgical sphincterotomy (SS)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Chemical sphincterotomy (CS)
Number of subjects: 279
Study: 16573163

Group type: EXPERIMENTAL
Intervention: Integrin and FAK antibody blocking
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 12710758

Group type: EXPERIMENTAL
Intervention: 25% metronidazole gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study: 11063284

Group type: EXPERIMENTAL
Intervention: Strong beliefs in shared autonomy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Strong beliefs in independent autonomy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Strong beliefs in paternalism
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Communication behaviors during decision making
Number of subjects: 36
Study: 9206079

Group type: EXPERIMENTAL
Intervention: Activity sensing rate adaptive ventricular pacing (VVIR)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fixed rate ventricular pacing (VVI)
Number of subjects: 19
Study: 1598954

Group type: EXPERIMENTAL
Intervention: norfloxacin ophthalmic solution 0.3%
Number of subjects: 488

Group type: COMPARATOR
Intervention: gentamicin ophthalmic solution 0.3%
Number of subjects: 488
Study: 6420445

Group type: EXPERIMENTAL
Intervention: naloxone (22 micrograms/min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 16
Study: 29606109

Group type: EXPERIMENTAL
Intervention: Apalutamide + degarelix
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo + degarelix
Number of subjects: 84
Study: 25882391

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Risperidone plus parent training
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 24191305

Group type: EXPERIMENTAL
Intervention: Dual therapy (ramipril and telmisartan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy (ramipril or telmisartan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both dual therapy and monotherapy
Number of subjects: 0
Study: 22301410

Group type: EXPERIMENTAL
Intervention: IL-2 therapy (6 million units, twice daily for 5 days at weeks 0, 8, and 16)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (ART alone)
Number of subjects: 148
Study: 20618582

Group type: EXPERIMENTAL
Intervention: Medication and medication referral as a treatment option
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Dedicated university class in psychopharmacology
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Training in psychotropic medications
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Diagnostic practices
Number of subjects: 322
Study: 18982034

Group type: EXPERIMENTAL
Intervention: 2 mL of 10% sodium fluorescein
Number of subjects: 1200

Group type: COMPARATOR
Intervention: 5 mL of 10% sodium fluorescein
Number of subjects: 1200
Study: 15186298

Group type: EXPERIMENTAL
Intervention: Relaxation training administered by school nurses
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 63
Study: 12167794

Group type: EXPERIMENTAL
Intervention: Mosaic bioprosthesis (Medtronic, Inc, Minneapolis, Minn)
Number of subjects: 561
Study: 9704736

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b (IFN) maintenance therapy (2 mU/m2 subcutaneously three times per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8583467

Group type: EXPERIMENTAL
Intervention: Random zero sphygmomanometer
Number of subjects: 62

Group type: COMPARATOR
Intervention: Automatic oscillometric BP monitor
Number of subjects: 62
Study: 2566293

Group type: EXPERIMENTAL
Intervention: Thymomodulin (80 mg daily orally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 28990

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: COMPARATOR
Intervention: Secobarbital 100 mg
Number of subjects: 76
Study: 30427741

Group type: EXPERIMENTAL
Intervention: V180 formulations with ISCOMATRIX™ adjuvant
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvanted formulations
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Unadjuvanted formulations
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: All 9 V180 formulations
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Formulations with ISCOMATRIX™ adjuvant
Number of subjects: 98

Group type: COMPARATOR
Intervention: Phosphate-buffered saline placebo
Number of subjects: 98
Study: 29369527

Group type: EXPERIMENTAL
Intervention: Preservative-free dexamethasone (DEX)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Diclofenac (DICL)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of DEX and DICL
Number of subjects: 180
Study: 27055444

Group type: EXPERIMENTAL
Intervention: Long-term interdisciplinary treatment (LG) - 10 sessions of cognitive behavioral therapy (CBT) and exercise training for 10 weeks.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Short-term interdisciplinary treatment (SG) - 2 full days of educational, exercise, and CBT programs.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (CG) - no intervention reported.
Number of subjects: 66
Study: 24739759

Group type: EXPERIMENTAL
Intervention: CDX-1401 vaccine with TLR agonists (resiquimod and Hiltonol)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CDX-1401 vaccine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CDX-1401 vaccine followed by immune-checkpoint inhibitors
Number of subjects: 45
Study: 23725789

Group type: EXPERIMENTAL
Intervention: FeFA with or without Zn
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: FeFA alone
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Zn alone
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Malaria incidence
Number of subjects: 247
Study: 20802899

Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PHACO)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Extracapsular extraction (ECCE)
Number of subjects: 205
Study: 19065903

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg per day + NXT 9 tablets per day
Number of subjects: 145

Group type: COMPARATOR
Intervention: Aspirin 100 mg per day
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study: 16317530

Group type: EXPERIMENTAL
Intervention: Percutaneous dorsal instrumentation (PER-G)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Open procedure (OP-G)
Number of subjects: 57
Study: 12798078

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 40
Study: 10892945

Group type: EXPERIMENTAL
Intervention: 20 parts per million inhaled nitric oxide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 40
Study: 9181997

Group type: EXPERIMENTAL
Intervention: BV pacing
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard RV pacing
Number of subjects: 8

Group type: COMPARATOR
Intervention: BV pacing off
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Follow-up at 6 +/- 6 months
Number of subjects: 8
Study: 1329478

Group type: EXPERIMENTAL
Intervention: lisinopril 5‐20 mg once daily
Number of subjects: 278

Group type: COMPARATOR
Intervention: enalapril 5‐20 mg once daily
Number of subjects: 278
Study: 3864225

Group type: EXPERIMENTAL
Intervention: Moderate sodium restriction from 200 to 50 mmol/day over 2 weeks in subjects with heredity of hypertension
Number of subjects: 62

Group type: COMPARATOR
Intervention: Moderate sodium restriction from 200 to 50 mmol/day over 2 weeks in subjects without heredity of hypertension
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Return to usual high sodium diet after 2 weeks of sodium restriction
Number of subjects: 62
Study: 31399377

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine
Number of subjects: 569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study: 29860922

Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 726
Study: 27887620

Group type: EXPERIMENTAL
Intervention: Skills training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture + e-module
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lecture + skills training + e-module
Number of subjects: 0
Study: 24804884

Group type: EXPERIMENTAL
Intervention: Immediate online MBCR (n = 30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait-list control (n = 32)
Number of subjects: 62
Study: 22492366

Group type: EXPERIMENTAL
Intervention: Sprinkles micronutrient powder (MNP)
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1063
Study: 19660268

Group type: EXPERIMENTAL
Intervention: Conventional thoracic sympathectomy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Simplified thoracic sympathectomy
Number of subjects: 32
Study: 18822978

Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (Madopa)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (Madopa)
Number of subjects: 60
Study: 16103254

Group type: EXPERIMENTAL
Intervention: Distal protection
Number of subjects: 191
Study: 12494258

Group type: EXPERIMENTAL
Intervention: Seven-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 0
Study: 10450448

Group type: EXPERIMENTAL
Intervention: High-dose ivermectin (up to 1600 micrograms/kg bodyweight)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard dose of ivermectin (150 micrograms/kg bodyweight)
Number of subjects: 100
Study: 7590390

Group type: EXPERIMENTAL
Intervention: Plasma ultrafiltrates collected 20 min after reperfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CF-containing postreperfusion samples from patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Superoxide dismutase
Number of subjects: 0
Study: 3130257

Group type: EXPERIMENTAL
Intervention: BAYo1248 (40 mg before breakfast)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: BAYm1099 (100 mg before breakfast and dinner)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (double-blind crossover study)
Number of subjects: 17
Study: 28450388

Group type: EXPERIMENTAL
Intervention: Drug-tolerant assay for detecting anti-drug antibodies (ADAs)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Drug-tolerant assay after optimization
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Drug-tolerant assay at the end of TAXIT
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: ADA Q4 patients
Number of subjects: 76

Group type: COMPARATOR
Intervention: ADA-negative patients and ADA Q1/Q2 patients
Number of subjects: 76
Study: 27061185

Group type: EXPERIMENTAL
Intervention: Computerized, patient-centered intervention educating Veterans about metabolic side effects and encouraging advocacy for monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control group)
Number of subjects: 0
Study: 25656074

Group type: EXPERIMENTAL
Intervention: In-person visits at home and/or in the community plus telephone and mail
Number of subjects: 151

Group type: COMPARATOR
Intervention: Telephone and mail only
Number of subjects: 151
Study: 23743803

Group type: EXPERIMENTAL
Intervention: 10-20 mmol sodium diet and sodium tablets (180 mEq/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Identical placebo tablets
Number of subjects: 32
Study: 19475576

Group type: EXPERIMENTAL
Intervention: Reduction in incontinence episode frequency (IEF) >40% to <=50%
Number of subjects: 1913

Group type: EXPERIMENTAL
Intervention: Reduction in IEF >70%
Number of subjects: 1913

Group type: EXPERIMENTAL
Intervention: Reduction in IEF >70% to <=80%
Number of subjects: 1913

Group type: EXPERIMENTAL
Intervention: Reduction in IEF >90% to <=100%
Number of subjects: 1913

Group type: EXPERIMENTAL
Intervention: Reduction in IEF <=40%
Number of subjects: 1913
Study: 17936036

Group type: EXPERIMENTAL
Intervention: Human Umbilical Vein (HUV) prosthesis
Number of subjects: 129

Group type: COMPARATOR
Intervention: Heparin-Bonded Dacron (HBD) prosthesis
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 129
Study: 20426759

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment interruption for > or =96 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Maintained antiretroviral therapy
Number of subjects: 38
Study: 15597104

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg m(‐2))
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Docetaxel, irinotecan, and lenogastrim (60 mg m(‐2), 200 mg m(‐2), and 150 microg m(‐2) day(‐1), respectively)
Number of subjects: 108
Study: 12110110

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate, 1000 mg intravenously
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (0.9% physiological saline, 10 ml)
Number of subjects: 120
Study: 9692160

Group type: COMPARATOR
Intervention: Fansidar alone
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Fansidar plus chloroquine
Number of subjects: 405
Study: 7928871

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 mg propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 mg propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3349842

Group type: EXPERIMENTAL
Intervention: Videotaped programs on bronchoscopic anatomy and pathology
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 65
Study: 11773918

Group type: EXPERIMENTAL
Intervention: Efegatran sulfate (overall)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Intermediate-dose efegatran
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Efegatran sulfate (high-dose)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Efegatran sulfate
Number of subjects: 336
Study: 29975272

Group type: EXPERIMENTAL
Intervention: ACB alone (15 mL of 0.5% bupivacaine)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ACB+PAI (15 mL of 0.5% bupivacaine + 50 mL of 0.25% bupivacaine with epinephrine)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: PAI alone (50 mL of 0.25% bupivacaine with epinephrine)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ACB+PAI
Number of subjects: 155

Group type: COMPARATOR
Intervention: ACB alone
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: PAI alone
Number of subjects: 155
Study: 26559637

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg once daily after breakfast
Number of subjects: 409

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily after breakfast
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 or 20 mg as maintenance therapy
Number of subjects: 409
Study: 24496699

Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg once daily for 4 weeks, followed by titration to 400 mg for the next 8 weeks.
Number of subjects: 432

Group type: COMPARATOR
Intervention: Olmesartan 20 mg once daily for 4 weeks, followed by titration to 40 mg for the next 8 weeks.
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg once daily, titrated to 400 mg, and olmesartan 20 mg, titrated to 40 mg, with possible addition of amlodipine (2.5-5 mg) and hydrochlorothiazide (6.25-25 mg) if BP target not attained.
Number of subjects: 432
Study: 23278573

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0